Alexion’s Soliris® (eculizumab) is a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris® has already been approved in the U.S., EU, and Japan as a first line treatment.
Last week, Russia approved the launch of an eculizumab biosimilar developed by Generium, a Moscow-based pharmaceutical company, partnering with Swiss/U.S. company Selexis, a company specializing in mammalian CHO-M cell line generation for protein expression